



Company	Ticker	Sector	Industry
Eli Lilly and Company	LLY-US	Health Care	Pharmaceuticals

## Business Description

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baxsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

## Price Chart

## Key Info & Metrics



<b>Empirical Research Rank:</b>	<b>1</b>
Date Purchased:	02/10/2022
Price:	\$339.68
52-Week Range:	\$234.69 - \$374.76
Dividend Yield:	1.15%
Market Cap (\$M):	\$335,306
Forward Price-to-Earnings:	39
<b>Total Return</b>	
Year-to-Date:	-7.2%
1 Year:	41.4%
3 Year:	143.5%
5 Year:	387.2%

## Investment Case - Updated: November 6, 2022

Eli Lilly produces and distributes over thirty different drugs, making it the second largest pharmaceutical company in the S&P 500 by market cap. The company's areas of expertise include diabetes (54 percent of revenue), oncology (21 percent), immunology (12 percent), and neuroscience (6 percent). Lilly introduced the first commercial insulin in 1923 and has regularly introduced new, improved formulations including longer-acting and easier-to-dose versions. Recently, Lilly launched an injectable medication, tirzepatide, a hormonal therapy that regulates blood sugar in adults with Type-2 diabetes. An alternative to insulin, this glucose-regulating treatment promotes weight loss, along with diet and exercise. The drug is under studies to treat obesity and cardiovascular diseases. Peak revenues could reach \$30 billion by 2030. In oncology, Lilly offers drugs that capitalize on the body's own immune system to fight cancer. We view the company's pipeline as the most exciting and potentially lucrative. In addition to new drugs for diabetes and immunology, Lilly is developing a treatment for Alzheimer's disease that could bring relief to millions of patients and generate billions of dollars, if approved.

## Disclaimer

CapFinancial Partners, LLC (dba "CAPTRUST") is a registered investment adviser. This report contains analysis/opinions as of the date of the report (subject to change without notice). This is not a recommendation to invest in an individual stock, but rather it is a summary of select data/statistics considered by CAPTRUST in making discretionary investment decisions (and may not include all relevant factors). Investing involves risk, so there is always a possibility of loss. Past performance is not a guarantee of future results. CAPTRUST (and/or associated persons) may engage in securities transactions in a manner inconsistent with the information contained herein.